Balchem Corporation reported record financial results for its fourth quarter and full year ended December 31, 2024. For the fourth quarter, net sales reached $240.0 million and adjusted EBITDA was $62.8 million, both representing record highs for the period.
All three business segments contributed to growth, with Human Nutrition & Health sales increasing by 6.8% to $147.3 million and its earnings from operations surging by 33.9% to $33.8 million. The Animal Nutrition & Health segment saw sales rise by 0.3% to $58.3 million, while Specialty Products sales grew by 6.0% to $32.9 million.
For the full year 2024, Balchem delivered record net sales and adjusted EBITDA, supported by strong free cash flow of $39.8 million in the fourth quarter. The company significantly strengthened its balance sheet by paying down $119.6 million of debt during the year, reducing net interest expense to $2.8 million in Q4 from $5.3 million in the prior year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.